How We're Winning the Fight Against Cancer

In today's Masters Series, adapted from the August 1, 2022 issue of the free Health & Wealth Bulletin e-letter, Doc details how cancer treatments have evolved over the past few years... explains why these medical breakthroughs are becoming more common... and reveals how you can profit as these advancements continue to take place... [Stansberry Research Logo] Delivering World-Class Financial Research Since 1999 [Stansberry Master Series] Editor's note: Many Americans are following the same playbook... They're giving away billions of dollars to fund advancements in medical research. And most of this funding is flowing into one area – cancer treatment. As a result, U.S.-based cancer firms are a great place to find value in the market today... That's why Retirement Millionaire editor Dr. David "Doc" Eifrig believes it's critical for investors to explore health care stocks to avoid missing out on this huge moneymaking opportunity. In today's Masters Series, adapted from the August 1, 2022 issue of the free Health & Wealth Bulletin e-letter, Doc details how cancer treatments have evolved over the past few years... explains why these medical breakthroughs are becoming more common... and reveals how you can profit as these advancements continue to take place... --------------------------------------------------------------- How We're Winning the Fight Against Cancer By Dr. David Eifrig, editor, Retirement Millionaire There's one statistic I want you to pay attention to today: 1 in 5. I'm not talking about unemployment or stock prices or any economic indicators. This is far more important. It is a matter of life and death. One in 5 people will die from cancer. That's based on recent death rates in the U.S., where cancer is the No. 2 leading cause of death, just after heart disease. So for every five people who die this year, one of those will be from cancer. That means it could be you, your spouse, your parents, or your children... Sadly, despite all the money and effort we've spent to battle cancer over the years, we've made little progress in overcoming cancer's lethal power. In fact, you might even see headlines that cancer death rates are down... but the truth is we're facing increased numbers of folks facing even deadlier cancers. That means the numbers will climb over the next few years. More alarmingly... about 40% of folks will face a cancer diagnosis in their lifetime, according to the National Cancer Institute. But there is hope. A new type of cancer therapy is quickly gaining traction in the medical world and showing great promise. It treats even some of the deadliest cancers... extending survival from months to years. If you or a loved one receives a cancer diagnosis, there are a few things you must do immediately. To start, you need to ask about the recommended treatment options. Make sure your doctor explains and spells out (preferably in writing) what he recommends for treatment. The traditional treatments for cancer include surgery, radiation, and chemotherapy. More often than not, doctors combine these treatments in various ways based on your specific cancer. They're known as the "cancer triad" and have been used together for decades. Surgery is fairly straightforward. It involves removing the tumor and as much affected tissue around it as possible. Radiation uses high-energy radiation waves (like gamma or X-ray waves) to focus in on the cancer and kill the DNA in the cancer cells. The problem, of course, is that radiation also causes cancer because it can mutate the DNA in healthy cells. Sometimes radiation might be used before surgery, for example, to shrink a tumor enough for it to be removed. Chemotherapy involves strong medications given at regular intervals. These drugs kill fast-replicating cells, meaning they target and kill cancer cells. But other fast-growing cells are also killed, including the ones lining your stomach (leading to nausea) and your hair (leading to hair loss). While we've seen advances in each of these three treatments as well as novel combinations of them to fight cancer, there's now a fourth option. It's currently being tested in dozens of clinical trials and some options are already on the market. This is the "Living Cure" I've written about many times. The Living Cure is immunotherapy. It's a way to train your body's own immune system to fight cancer. That means the power to beat cancer is already inside of you. Doctors just need to figure out the best way to turn it on. Immunotherapy started out when scientists found a man with a facial tumor who got a bacterial infection near the tumor. His body went into overdrive to fight the infection and also wound up attacking and killing the tumor. That was enough to spur the birth of this new cancer treatment option. In 2013, immunotherapy was named "Breakthrough of the Year" by Science magazine. That's on par with past breakthroughs such as sequencing the entire human genome and cloning a living mammal. And in 2018, two of the pioneers of immunotherapy research won the Nobel Prize in physiology or medicine for their work. This is truly a game changer for how we treat – and cure – cancer. --------------------------------------------------------------- Recommended Links: [Doc: Biggest Announcement in 40 Years]( Dr. David Eifrig just stepped forward with one of the biggest announcements of his 40-year career. It's an AI play almost no one is paying attention to... and the potential for your retirement could be far bigger than Nvidia. In fact, seeing this story could help save your life. Every reader needs to see this update immediately. [Click here for details](. --------------------------------------------------------------- ['I'd Feel Secure Putting 50% of My Daughters' Inheritance in THIS Stock']( The man CNBC called "The Prophet" bought Apple at $0.35 per share and Amazon for less than $2.50 per share. Now, he says ONE stock could be the single smartest way to pass wealth to your family. It has outperformed traditional inheritance vehicles like annuities, life insurance, real estate, and gold... by as much as 13 times, with tax advantages not many other investments offer. [He reveals the name and ticker symbol in his recent interview, 100% free of charge](. --------------------------------------------------------------- At the time of this writing, 11 immunotherapy drugs have received U.S. Food and Drug Administration ("FDA") approval, but more are in testing phases. We've seen promising results for even the deadliest cancers. Melanoma and liver cancer in particular have seen fantastic trials with patients living much longer after diagnosis than ever before. The best responses come from combination therapies. These combine immunotherapy with chemotherapy or radiation. The idea is that chemotherapy may already stimulate the immune system, but it needs a boost from immunotherapy to work better. Some tumors are "cold," meaning they are shut off from the immune system's attacks. New research looks at how immunotherapy drugs can turn on these cold tumors to make them vulnerable to chemotherapy drugs. That's why certain combinations could take down the tumors' defenses and then kill them. There are now approved options for cancers of the bladder, breast, kidney, and even some blood cancers. In 2018, the FDA also approved a few immunotherapy drugs for first-line treatment. That means patients don't have to endure rounds of radiation and chemotherapy first and only start immunotherapy as a "last chance" effort. They can get immunotherapy first. One of those first-line options now focuses on advanced triple-negative breast cancer. This is one of the most difficult types of breast cancer to treat, so hitting it right away with immunotherapy shows a lot of promise. Eventually, we hope to see immunotherapy options available for all cancers as first-line options or in combination with other treatments. Imagine a day when you get a cancer diagnosis and it's immediately sequenced to determine the genetic makeup. Then you get a personalized treatment that's tailored exactly to your cancer. It could mean the difference between months or years of uncertainty versus total remission. That's the future we want to see. Immunotherapy is just one of the medical breakthroughs I've followed and detailed for my readers. And I expect many more to come... We're all customers when it comes to the $4 trillion health care industry. Because of that, demand in the sector will only increase as medical science makes advances we could only dream about. What's more, the pandemic catalyzed innovation. The technology available today will be embraced and deployed across the spectrum of care. The time to invest is now. With the U.S. population growing older, the need for health care is only going to increase. Health care customers will demand access to new lifesaving and life-improving medicines and treatments. That's why now is the time to invest – not only in health care but in your personal health as well – while we're still in the early stages of this development. Here's to our health, wealth, and a great retirement, Dr. David Eifrig and the Health & Wealth Bulletin Research Team --------------------------------------------------------------- Editor's note: These cancer treatment advancements aren't the only tailwind Doc is paying attention to right now. You see, he believes the artificial intelligence developments we've seen over the past few years are setting the stage for a slew of buying opportunities... That's why he hosted an online presentation this week to talk about how you can capitalize on this unique setup and earn massive returns. [Learn more here](... You have received this e-mail as part of your subscription to Stansberry Digest. If you no longer want to receive e-mails from Stansberry Digest [click here](. Published by Stansberry Research. You’re receiving this e-mail at {EMAIL}. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberryresearch.com. Please note: The law prohibits us from giving personalized financial advice. © 2024 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 or [stansberryresearch.com](. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Stansberry Research does not recommend or endorse any brokers, dealers, or investment advisors. Stansberry Research forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Stansberry Research (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.